Carteolol
Based on 2 publication(s) in Google Scholar
Carteolol is a non-selective β-adrenoceptor antagonist. Carteolol induces apoptosis via a caspase activated and mitochondrial-dependent pathway. Carteolol can be used for glaucoma research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 51781-06-7
- Fòrmula: C16H24N2O3
- Peso molecular:292.37
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Carteolol
MoreVer todos los productos específicos de isoformas Adrenergic Receptor
MoreVer todos los productos específicos de isoformas Caspase
More
Actividad biológica
Descripciòn
In Vitro
Carteolol (0-2%; 0-28 hours; HCECs) has cytotoxicity and decreases cell viability in a dose- and time-dependent manner[1].
Carteolol (0.25%; 4-12 hours; HCECs) induces apoptosis and necroptotic protein expression in HCECs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCECs
-
Concentration:0.00390625-2%
-
Incubation Time:0, 2, 4, 8, 16, 20,24 and 28 hours
-
Result:Decreased cell viability with the concentrations above 0.0015625% in a dose- and time-dependent manner.
-
Cell Line:HCECs
-
Concentration:0.25%
-
Incubation Time:4, 8 and 12 hours
-
Result:Dampened expression of the anti-apoptotic protein Bcl-2 and Bcl-xL, enhanced expression of the pro-apoptotic proteins Bax and Bad, and mitochondrial-released pro-apoptotic proteins Cyt.c and AIF.
-
Cell Line:HCECs
-
Concentration:0.25%
-
Incubation Time:4, 8 and 12 hours
-
Result:Increased the number of G1 phase of the cell cycle, whereas decreased S phase.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 51781-06-7
-
Peso molecular 292.37
-
Fòrmula C16H24N2O3
-
SMILES
O=C1NC2=C(C(OCC(O)CNC(C)(C)C)=CC=C2)CC1
-
Synonyms
OPC-1085
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
ACS Omega
Computational and Experimental Approaches Identify Beta-Blockers as Potential SARS-CoV-2 Spike Inhibitors. [Abstract]2022 Aug 8;7(32):27950-27958. PMID: 35983371 -
J Pharm Biomed Anal
Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]2021 Feb 20:195:113870. PMID: 33453569
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Carteolol Related Classifications
HY-17495 Related Classifications
Powered by Bioz